Authors: Kalfas S, Visvanathan K, Chan K, Drago J. doi: https://doi.org/10.1101/2020.11.30.20236570 Abstract Introduction Ivermectin is a commonly used antihelminthic agent with over 35 years of established safety data in humans. Recent data demonstrates antiviral activity in vitro against SARS-CoV-2, in addition to a range of viruses. In vitro and animal models also provide evidence of [...]

Authors: Peralta EG, Fimia-Duarte R, Cardenas JW, Dominguez DV, Segura RB Abstract Covid-19 is one of the viral infections that have always accompanied us. In some years harmless, but from time to time with a higher risk potential. What is particularly unsettling for us is that transmission often occurs from a [...]

Background Ivermectin is one among several potential drugs explored for its therapeutic and preventive role in COVID-19 infection. The study was aimed to explore the association between ivermectin prophylaxis and development of COVID-19 infection among healthcare workers.

Authors: Chamie J Abstract In these eight Peruvian State analyses, Ivermectin distributions preceded sound reductions in excess deaths and case fatality rate (CFR). The variation in the number of detected cases nor the vulnerable population decrease can explain this reduction. Other possible explanations, such as cross-immunity with dengue, or mere causality, have been discarded due [...]

Authors: Lehrer S, Rheinstein PH PMID: 32871846 PMCID: PMC7652439 DOI: 10.21873/invivo.12134 Abstract Background/aim: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One drug that has attracted interest is the antiparasitic compound ivermectin, a macrocyclic lactone derived from the bacterium Streptomyces avermitilis. We carried out a docking [...]

Authors: DiNicolantonio JJ, Barroso-Arranda J, McCarty M PMID: 32895293 PMCID: PMC7476419 DOI: 10.1136/openhrt-2020-001350 Abstract Ivermectin, on the WHO’s List of Essential Medications, has been in clinical use since 1981 as an orally and topically active agent for treating a range of parasitic infections in humans, including river blindness and lymphatic filariasis. It is also widely [...]

Authors: Jans DA, Wagstaff KM PMID: 32942671 PMCID: PMC7564151 DOI: 10.3390/cells9092100 Abstract The small molecule macrocyclic lactone ivermectin, approved by the US Food and Drug Administration for parasitic infections, has received renewed attention in the last eight years due to its apparent exciting potential as an antiviral. It was identified in a high-throughput chemical screen [...]

Authors: Swargiary A DOI: https://doi.org/10.21203/rs.3.rs-73308/v1 Abstract Purpose: COVID-19, caused by SARS-CoV2 virus is a contagious disease affecting millions of lives throughout the globe. Currently, there are no clinically approved drugs for SARS-CoV2 although some drugs are undergoing clinical trials. The present study investigates the binding property of ivermectin on four important drug targets, spike protein, [...]

Authors: DiNicolantonio JJ, Barroso-Arranda J, McCarty M PMID: 32895293 PMCID: PMC7476419 DOI: 10.1136/openhrt-2020-001350 Abstract Ivermectin, on the WHO’s List of Essential Medications, has been in clinical use since 1981 as an orally and topically active agent for treating a range of parasitic infections in humans, including river blindness and lymphatic filariasis. It is also widely [...]

Authors: Mudatsir M, Yufika A, Nainu F, Frediansyah A, Megawati D doi: https://doi.org/10.3390/scipharm88030036 Abstract The coronavirus disease 2019 (COVID-19) pandemic is a major global threat. With no effective antiviral drugs, the repurposing of many currently available drugs has been considered. One such drug is ivermectin, an FDA-approved antiparasitic agent that has been shown to exhibit [...]